Show results for
Refine by
Neck Cancer Suppliers Serving Congo
13 companies found
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
BioMark’s initial liquid biopsy assay detects SSAT1 using an FDA approved drug. SSAT1 is an enzyme with elevated levels in numerous cancers. The assay targets a well researched and understood metabolic pathway. BioMark of a few unique ...
based inCarlton, AUSTRALIA
Radiopharm Theranostics has the ambition to become a recognised leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. There is unique potential of ...
AVβ6 is the invention of internationally regarded integrin expert Professor Johannes Notni, formerly at the Technical University of Munich and now Professor at Essen University. ...
based inMelbourne, AUSTRALIA
Starpharma Holdings Limited is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP drug delivery and ...
DEP® cabazitaxel is an enhanced version of leading prostate cancer drug cabazitaxel (Jevtana®). Cabazitaxel (Jevtana®) had global sales of €536M in 2020 despite having multiple US FDA “Black Box” warnings. ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
based inPearl River, NEW YORK (USA)
Auro Vaccines LLC is a clinical-stage vaccine development company pioneering a major evolutionary step in the design and development of preventive and therapeutic vaccines for infectious diseases. Our novel approach is based on a proprietary ...
Auro Vaccines is developing a GeneVax prime/VesiculoVax boost therapeutic HPV vaccine for use as an adjunct to surgery that targets the seven HPV types responsible for more than 92% of cervical and head and neck ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
Dubermatinib (TP-0903) is an investigational inhibitor of AXL receptor tyrosine kinase (RTK), a protein known to be involved in acquiring resistance to chemotherapeutics, immune evasion, and developing metastatic capacity in cancer ...
based inAtlanta, GEORGIA (US) (USA)
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ prepared from a ...
Metaclipse Therapeutics Corporation is developing novel personalized vaccine immunotherapies for cancer. MembrexTM, a proprietary platform approach tailored to each patient and their specific tumor, consists of ‘membrane vesicles’ ...
based inHENFIELD, UNITED KINGDOM
A trusted and established manufacturer of gamma probe systems. Since 1986 Care Wise have been a trusted and established manufacturer of gamma probe systems. Previously based in Morgan Hill, CA, USA, the company has always been at the forefront of ...
This device has now been superseded by the C-Trak Apollo gamma probe system and is no longer available. Gamma Probe for Sentinel Node Biopsy: Accurate and precise gamma probe for detection of radiation for use during sentinel node biopsies, allowing ...
based inSunnyvale, CALIFORNIA (USA)
IntraOp is the leading innovator of electron therapy devices for treating cancer. IntraOp’s compact and mobile linear accelerators enable oncologists to deliver effective, precise, and affordable radiation therapy at the point of care. The Mobetron ...
Our flagship product—the Intraop® Mobetron®—is used by the leading cancer physicians in the best hospitals, clinics and academic centers in the world. The Mobetron is the first mobile, self-shielded electron-beam linear ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
MIT-001 is expected to meet the medical need for oral mucositis for which there is no cure. It aims to be a first-in-class drug that can be used by both patients with head and neck cancer or hematological ...
based inAhrensburg, GERMANY
The biotechnology company Abviris Deutschland GmbH, based in Ahrensburg, Germany, is a pioneer in HPV serology, developing innovative, next generation, products such as Prevo-Check® for early detection and post-treatment monitoring of HPV-induced ...
based inPeachtree Corners, GEORGIA (US) (USA)
Guided Therapeutics, Inc. (OTC: QB GTHP) is committed to developing groundbreaking medical devices using our patented biophotonic technology to detect diseases earlier, more accurately, and more efficiently than other tests. Since Guided ...
Our patented technology, which features our flagship product the LuViva® Advanced Cervical Scan, uses biophotonics to detect both physical and chemical changes in tissues that are early signs of cancer. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has ...